Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether adding everolimus to hormone treatment before
breast surgery will increase the chances of shrinking the breast cancer in those patients
with hormone-responsive breast cancer and a lower Oncotype DX® Recurrence Score ( 25 or
less), compared to prior experience with hormone therapy alone. Everolimus is a drug
currently approved for use by the United States Food and Drug administration (FDA) for the
treatment of patients with advanced or metastatic kidney or breast cancer. Everolimus is
considered investigational for non-metastatic breast cancer patients.